Kodiak Sciences Inc.
KOD
주식 순위
#3153
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
주가
$90.83
마지막 동기화: 2026-10-19
시가총액
$5.71B
변동 (1일)
5.92%
변동 (1년)
413.16%
국가
US
거래 Kodiak Sciences Inc. (KOD)
카테고리
Healthcare
Kodiak Sciences Inc. (KOD)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 0.00
Kodiak Sciences Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0.00입니다. 2023년 말 기준 P/S 비율은 0.00였습니다.
Kodiak Sciences Inc.의 P/S 비율 기록 (2016 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
